Avastin and Herceptin sales fuel Genentech income rise

Share this article:
Genentech reported a third-quarter net income that rose 56 percent aided by sales of its colon cancer drug Avastin (bevacizumab) and breast cancer drug Herceptin (trastuzumab).
 Avastin sales rose 78 percent to $325.2 million. Sales of breast cancer drug Herceptin rose 70 percent to $215 million.
Although sales of Avastin leveled off for its FDA-approved indication, colon cancer, doctors are starting to use it off-label for breast and lung cancer. Off-label prescribing has also boosted sales of Herceptin. The drug is approved for the treatment of metastatic breast cancer in certain women, however doctors are trying it in earlier stages of the disease.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...